Katharine C. Hsu: Publications

Goldberg JD, Linker A, Kuk D, Raten R, Jurcic J, Barker JN, Castro-Malaspina H, Giralt S, Hsu K, Jakubowski AA, Jenq R,Koehne G, Papadopoulos EB, van den Brink MR, Young JW, Boulad F, Kernan NA,O’Reilly RJ, Prockop SE, Yahalom J, Heller G, Perales MA. T-cell depleted stem-cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in 1st complete remission with a decreased risk of graft-versus-host disease. Biol Blood Marrow Transplant. 2013; 12:208-13.

Pittari G, Liu XR, Selvakumar A, Zhao Z, Merino E, Huse M, Chewning JH, Hsu KC, Dupont B. NK cell tolerance of self-specific activating KIR2DS1 in individuals with cognate HLA-C2 ligand. J immunol. 2013; 190: 4650-4660. {PMID:23554313]

Tarek, N, Gallagher MM, Zheng J, LeLuduec JB, Venstrom JM, Chamberlain E, Modak S, Heller G, Dupont B, Cheung NK, Hsu KC. Unlicensed natural killer cells target neuroblastoma following anti-GD2 antibody treatment. J. Clin. Invest. 2012; 122: 3260-3270.

Venstrom JM, Pittari G, Gooley TA, Chewning JH, Spellman S, Haagenson M, Gallagher MM, Malkki M, Petersdorf E, Dupont B, Hsu KC. HLA-C-dependent prevention of leukemia relapse by donoractivating KIR2DS1. N Engl J Med. 2012; 367:805-816.

Jelčić I*, Hsu KC*, Kakalacheva K, Breiden P, Dupont B, Uhrberg M, Martin R, Münz C, Lünemann JD. Killer immunoglobulin-like receptor locus polymorphisms in Multiple Sclerosis. Mult Scler. 2012 Jul;18(7):951-8. Epub 2011 Dec 20. *Equally contributing first authors.

Cheung IY, Hsu K, Cheung NK. Activation of peripheral blood granulocytes and patient outcome following immunotherapy with anti-GD2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor.  Clin Oncol. 2012 Feb 1;30(4):426-32. Epub 2011 Dec 27. 

Ponce DM, Zheng J, Gonzales A, Lubin M, Heller G, Castro-Malaspina H, Giralt S, Hsu K, Jakubowski AA, Jenq RR, Koehne G, Papadopoulos EB, Perales MA, van den Brink MR, Young JW, Boulad F, Kernan NA, Kobos R, Prockop S, Scaradavou A, Small T, O'Reilly RJ, Barker JN. Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011 Sep;17(9):1316-26. Epub 2011 Jan 11.

Jakubowski AA, Small TN, Kernan NA, Castro-Malaspina H, Collins N, Koehne G, Hsu KC, Perales MA, Papanicolaou G, van den Brink MRM, O'Reilly RJ, Young JW, Papadopoulos EB. T-cell depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies. Biol Blood Marrow Transpl. 2011. Jan 11 [Epub ahead of print].

Perales MA, Jenq R, Goldberg JD, Wilton AS, Lee SS, Castro-Malaspina HR, Hsu K, Papdopoulos EB, van den Brink MR, Boulad F, Kernan NA, Small TN, Wolden S, Collins NH, Chiu M, Heller G, O'Reilly RJ, Kewalramani T, Young JW, Jakubowski AA. Second-line age-adjusted International Prognostic Index in patients with advanced non-Hodgkin lymphoma after T-cell depleted allogeneic hematopoietic SCT. Bone Marrow Transplant. 2010; 45: 1408-1416.

Venstrom JM, Gooley TA, Spellman S, Pring J, Malkki M, Dupont B, Petersdorf E, Hsu KC. Donor activating KIR3DS1 is associated with decreased acute GvHD in unrelated allogeneic hematopoietic stem cell transplantation. Blood. 2010; 115: 3162-3165.

Venstrom JM, Zheng J, Noor N, Danis KE, Yeh AW, Cheung IY, Dupont B, O'Reilly RJ, Cheung NV, Hsu KC. KIR and HLA Genotypes are associated with improved survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Canc Res. 2009; 15: 7330-7334. *Article highlighted in Nature Reviews Clinical Oncology, Jan 2010.

Yu J, Venstrom JM, Liu XR, Pring J, Hasan RS, O'Reilly RJ, Hsu KC. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function following T-cell depleted allogeneic hematopoietic cell transplantation. Blood. 2009; 113: 3875-3884.

Shi J, Tricot G, Szmania S, Rosen N, Garg TK, Malaviarachchi PA, Moreno A, Dupont B, Hsu KC, Baxter-Lowe LA, Cottler-Fox M, Shaughnessy JD, Barlogie B, van Rhee F. Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation. Brit. J. Hematol. 2008; 143: 641-653.

Ostronoff F, Perales M-A, Stubblefield MD, Hsu KC. Rituximab-responsive Guillain-Barre Syndrome following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2008; 42: 71-2.

Castro-Malaspina H, Jakubowski AA, Papdopoulos EB, Boulad F, Young JW, Kernan NA, Perales MA, Small TN, Hsu K, Chiu M, Heller G, Collins NH, Jhanwar SC, van den Brink M, Nimer SD, O'Reilly RJ. Induction of remission prior to transplantation improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell depleted stem cell transplants from HLA-identical siblings. Biol Blood Marrow Transpl. 2008; 14:458-468.

Kim S, Sunwoo JB, Yang L, Choi T, Song Y, French AR, Vlahiotis A, Piccirillo JF, Cella M, Colonna M, Mohanakumar T, Hsu KC, Dupont B, Yokoyama WM. HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci USA. 2008; 105: 3053-8.

Yu J, Heller G, Chewning JH, Kim S, Yokoyama W, Hsu KC. Diversity and hierarchy of the human natural killer cell response are determined by inhibitory receptors for self-HLA-B and HLA-C ligands. J Immunol. 2007; 179: 5977-89.

Chewning JH, Castro-Malaspina H, Jakubowski A, Kernan NA, Papadopoulos EB, Small TN, Heller G, Hsu KC, Perales MA, van den Brink MRM, Young JW, Prockop SE, Collins NH, O'Reilly RJ, Boulad F. Fludarabine-based conditioning secures engraftment of second heamtopoietic stem cell allografts (HSCT) in the treatment of initial graft failure. Biol Blood Marrow Transpl. Biol Blood Marrow Transpl. 2007; 13: 1313-1323.

Jakubowski AA, Small TN, Young JW, Kernan NA, Castro-Malaspina H, Hsu K, Perales MA, Collins N, Cisek C, Chiu M, van den Brink MRM, O'Reilly RJ, Papadopoulos EB. T-cell depleted stem cell transplantation fro adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of anit-thymocyte globulin. Blood. 2007; 110: 4552-4559.

Chewning JH, Gudme CN, Hsu KC, Selvakumar A, Dupont B. KIR2DS1-positive NK cells mediate alloresponse against the C2 HLA-KIR Ligand Group in vitro. J Immunol. 2007; 179: 854-868.

Small TN, Young JW, Prockop S, Castro-Malaspina H, Wilton A, Heller G, Boulad F, Chiu M, Hsu KC, Jakubowski A, Kernan NA, Perales MA, O'Reilly RJ, Papadopoulos E. Intravenous busulfan and melphalan, tacrolimus and short course methotrexate followed by an unmodified HLA matched related or unrelated hematopoetic stem cell transplant (HSCT) for the treatment of advanced hematologic malignancies. Biol Blood Marrow Transpl., 2007; 13: 235-244.

Hsu KC, Pinto-Agnello C, Gooley T, Malkki M, Dupont B, Petersdorf EW, IHWG HCT-KIR Component, Hematopoietic stem cell transplantation: killer immunoglobulin-like receptor component. Tissue Antigens 2007; 69 Suppl. 1: 1-4.

Hsu K, Gooley T, Malkki M, Pinto-Agnello C, Dupont B, Bignon J, Bornauser M, Christiansen F, Gratwohl A, Morishima Y, Oudshoorn M, Ringden O, van Rood JJ, Petersdorf E, International Histocompatibility Working Group. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrrow Transpl. 2006; 12: 828-836.

Kesh S, Mensah NY, Peterlongo P, Jaffe D, Hsu K, van den Brink M, O'Reilly R, Pamer E, Satagopan J, Papanicolaou GA. TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Ann NY Acad Sci 2005; 1062: 95-103.

Hsu KC, Taylor CA, O'Reilly RJ, Horowitz MM, Arkun K, Pinto C, Dupont B. Improved outcome in HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005; 105: 4878-4884.

Marsh SGE, Parham P, Dupont B, Geraghty DE, Trowsdale J, Middleton D, Vilches C, Carrington M, Witt C, Guethlein LA, Shilling H, Garcia CA, Hsu KC, Wain H. Killer immunoglobulin-like receptor (KIR) Nomenclature Report, 2002. Immunogenetics 2003; 55:220-226.

Hsu KC, Liu X, Selvakumar A, Mickelson E, O'Reilly RJ, Dupont B. Killer Ig-like receptor (KIR) haplotype analysis by gene content: evidence for genomic diversity with a minimum of six basic framework haplotypes, each with multiple subsets. J Immunol 2002; 169:5118-5129.